Olympus Corporation (TYO:7733)

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Japan Revenue	104.00B	103.91B	110.53B
North America Revenue	425.02B	405.49B	413.90B
Europe Revenue	291.77B	281.07B	254.62B
China Revenue	81.94B	82.45B	95.74B
Asia and Oceania Revenue (Post-FY2019 Reporting)	105.48B	102.59B	93.71B
Asia and Oceania Revenue (Pre-FY2020 Reporting)	187.42B	185.04B	189.45B
Other Countries Revenue	36.41B	35.17B	28.84B

Revenue Breakdown

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Gastrointestinal Solutions Division Revenue	726.78B	697.36B	674.04B
Surgical & Interventional Solutions Division Revenue	317.60B	313.11B	322.76B

Revenue Breakdown 2

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Endoscopic Solutions Division Revenue	636.14B
Therapeutic Solutions Division Revenue	360.66B
Total Medical Solutions Division Revenue	996.80B
Other Division Revenue (Post-FY2024 Reporting)	530.00M

EBIT

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Gastrointestinal Solutions Division Operating Profit	156.86B	136.36B	171.44B
Surgical & Interventional Solutions Division Operating Profit	-15.53B	-14.99B	15.27B

EBIT 2

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Endoscopic Solutions Division Operating Profit	141.40B
Therapeutic Solutions Division Operating Profit	61.45B
Total Medical Solutions Division Operating Profit	202.85B
Other Division Operating Profit (Post-FY2024 Reporting)	-473.00M
Eliminations from Division Operating Profit	-39.92B

Key Performance Indicators

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment	-	3.00%
ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment	-	5.00%
ESD - Medical Service Revenue Growth Rate After FX Adjustment	-	5.00%
Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment	-	4.00%
TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment	-	2.00%
TSD - Urology Revenue Growth Rate After FX Adjustment	-	6.00%
TSD - Respiratory Revenue Growth Rate After FX Adjustment	-	10.00%
TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment	-	-7.00%
Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment	-	3.00%
GSD - GI Endoscopy Revenue Growth Rate After FX Adjustment	1.00%	-
GSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment	4.00%	-
GSD - Medical Service Revenue Growth Rate After FX Adjustment	3.00%	-
Total Gastrointestinal Solutions Division Revenue Growth Rate After FX Adjustment	2.00%	-
SIS - Respiratory Revenue Growth Rate After FX Adjustment	1.00%	-
SIS - Surgical Endoscopy Revenue Growth Rate After FX Adjustment	-6.00%	-
SIS - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment	-15.00%	-
Total Surgical & Interventional Solutions Division Revenue Growth Rate After FX Adjustment	-4.00%	-

Data Source: Fiscal.ai Last updated: Jun 30, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 13, 2026

Data Sources Report a data error